The estimated Net Worth of R.A. Ii Session is at least $21.6 Millón dollars as of 12 July 2023. Mr Session owns over 85,872 units of Taysha Gene Therapies stock worth over $20,582,453 and over the last 8 years he sold TSHA stock worth over $389,571. In addition, he makes $634,626 as Founder, Pres y CEO & Director at Taysha Gene Therapies.
Sign up
Mr II TSHA stock SEC Form 4 insiders trading
Mr has made over 4 trades of the Taysha Gene Therapies stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 85,872 units of TSHA stock worth $60,969 on 12 July 2023.
The largest trade he's ever made was selling 434,615 units of Taysha Gene Therapies stock on 20 June 2023 worth over $308,577. On average, Mr trades about 49,301 units every 50 days since 2017. As of 12 July 2023 he still owns at least 8,871,747 units of Taysha Gene Therapies stock.
You can see the complete history of Mr Session stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. R. A. Session II biography
R. A. Session II is the Founder, Pres, CEO & Director at Taysha Gene Therapies.
What is the salary of Mr II?
As the Founder, Pres y CEO & Director of Taysha Gene Therapies, the total compensation of Mr II at Taysha Gene Therapies is $634,626. There are 1 executives at Taysha Gene Therapies getting paid more, with Kamran Alam CPA, M.B.A. having the highest compensation of $756,381.
How old is Mr II?
Mr II is 42, he's been the Founder, Pres y CEO & Director of Taysha Gene Therapies since . There are 2 older and no younger executives at Taysha Gene Therapies. The oldest executive at Taysha Gene Therapies, Inc. is Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, 51, who is the Chief Medical Officer and Head of R&D.
What's Mr II's mailing address?
R's mailing address filed with the SEC is 2275 Half Day Rd #3160, Deerfield, IL 60015, USA.
Insiders trading at Taysha Gene Therapies
Over the last 4 years, insiders at Taysha Gene Therapies have traded over $3,159,500 worth of Taysha Gene Therapies stock and bought 21,030,825 units worth $24,949,013 . The most active insiders traders include Paul B Manning, John A Iii Stalfort y R.A. Ii Session. On average, Taysha Gene Therapies executives and independent directors trade stock every 44 days with the average trade being worth of $1,947,009. The most recent stock trade was executed by Paul B Manning on 27 June 2024, trading 1,333,333 units of TSHA stock currently worth $2,999,999.
What does Taysha Gene Therapies do?
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
What does Taysha Gene Therapies's logo look like?
Complete history of Mr Session stock trades at Taysha Gene Therapies
Taysha Gene Therapies executives and stock owners
Taysha Gene Therapies executives and other stock owners filed with the SEC include:
-
Kamran Alam CPA, M.B.A.,
Chief Financial Officer -
R. A. Session II,
Founder, Pres, CEO & Director -
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M,
Chief Medical Officer and Head of R&D -
Dr. Claire Aldridge Ph.D.,
Sr. VP & Chief of Staff and Bus. Operations -
Emily McGinnis M.P.H.,
Chief Patient Officer & Head of Gov. Affairs -
Tracy M. Porter,
Chief People Officer -
Timothy J. Douros J.D.,
Chief Legal Officer & Corp. Sec. -
Dr. Kimberly Lee D.O.,
Sr. VP of Corp. Communications & Investor Relations -
Jim Rouse,
Chief Information Officer -
Frederick Porter Ph.D.,
Chief Technical Officer -
Paul B Manning,
-
Laura Sepp Lorenzino,
-
R.A. Ii Session,
-
Sean P. Nolan,
Chief Executive Officer -
Suyash Prasad,
CMO and Head of R&D -
Kathleen Reape,
Director -
John A Iii Stalfort,
-
Alison S Long,
-
Phillip B. Donenberg,